NOTE: hsa-miR-29c* mentioned in the following paper is the retired name for what is now hsa-miR-29c-5p: http://www.mirbase.org/cgi-bin/mature.pl?mature_acc=MIMAT0004673
PHILADELPHIA and REHOVOT, Israel, Feb. 7, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study demonstrating the ability of microRNA expression to serve as a biomarker to predict the progression of bladder urothelial carcinoma were published online in the British Journal of Urology International, in an article entitled, “Predicting progression of bladder urothelial carcinoma using microRNA expression.” The article can be accessed online at http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2012.11748.x/abstract and is expected to be published in the print edition of the British Journal of Urology International.
In the study, formalin-fixed, paraffin-embedded samples of 108 non-muscle invasive (“NMI”) bladder carcinomas, and 29 muscle invasive tumors, were collected and highly specific microRNA expression levels were measured by Rosetta Genomics’ microarray technology. Using micro-dissection, specific tumor microRNAs were chosen to be included in the study in order to avoid background contamination derived from surrounding tissue. The study found that the expression level of one microRNA, miR-29c*, was significantly under-expressed in tumors that progressed and could be used to stratify bladder cancer patients into risk groups.
The study showed that significantly higher expression of miR-29c* was detected in NMI bladder tumors that did not progress compared with lesions that did progress. The lower expression of miR-29c* in patients that later progressed was similar to the expression levels seen in patients with muscle invasive disease.
Prediction of recurrence and progression is currently based upon clinical and pathological factors such as: tumor grade, tumor stage, number of lesions, tumor size, prior recurrence rate and presence of concomitant carcinoma in-situ (“CIS”). These factors are not [click to continue…]
Incoming search terms for this article:
PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis, in an article entitled “Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.” The article can be viewed online at http://www.ncbi.nlm.nih.gov/pubmed/23124598.
The study assessed microRNA differences between CUP metastases with favorable prognosis and metastases of known primary tumors in order to screen for an aggressive, pro-metastatic, CUP-specific biologic signature.
The study consisted of two stages. In the first stage, metastases obtained from CUP cases were assigned to a primary tissue of origin using Rosetta’s miRview® mets2 microarray assay and compared to pathological and clinical presentation. In the second stage, the expression of 733 microRNAs was examined in CUP tumors classified as breast, serous ovarian and upper squamous cancers and compared to that of matched KPMs.
The study evaluated approximately 100 CUP and KPM tumors and found no unique microRNA signature differentiating CUP presentation from that of metastases of known primaries. This supports current gold standard treatment for [click to continue…]
Incoming search terms for this article:
Medicare-Covered Assay Accurately Identifies Tumor of Origin in Cancer of Unknown Primary
PHILADELPHIA, REHOVOT, Israel, and PITTSBURGH, Oct. 2, 2012 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, and Precision Therapeutics, Inc. (PTI), a life science company known for its expertise in the science of personalizing cancer therapy by advancing genomic testing and bioinformatics, today announced the commercial launch of the miRview® mets2 assay in the U.S. oncology market.
miRview® mets2, Rosetta Genomics’ flagship product, is an innovative diagnostic tool for clinicians in the evaluation of their Cancer of Unknown/Uncertain Primary (CUP) patients. Rosetta and PTI will be co-promoting the product in the U.S. and active promotion by both companies has commenced.
“We are excited to launch our co-promotional activities with PTI as we are confident that our combined efforts will make our miRview® mets2 assay more broadly available to the 200,000 patients diagnosed with CUP each year in the U.S. The accurate diagnosis of [click to continue…]
Incoming search terms for this article:
The miREC database (miRNAs involved in Endometrial Cancer) combines published data about miRNAs and genes deregulated in endometrial cancer, as well as target-regulator relationships between these genes and miRNAs. All information has been extracted from published literature and entries are supplemented by reference citations.
The miREC database was launched in February 2011 by researchers at the Systems Biology Research Centre, University of Skövde, Sweden. Latest update was in March 201. Currently, miREC contains 570 genes and 154 miRNAs. These comprise genes and miRNAs found through manual curation of published literature, as well as their verified regulators and targets from miRecords and TarBase.
http://www.mirecdb.org/
Very last minute – but if you are near London and don’t have any plans for Wednesday this might be right event for you:
The third international symposium on Cancer, microRNAs and other non-coding RNAs will highlight the function and regulation of non-coding RNAs during oncogenesis. The symposium will cover a wide range of themes, from the basic biology of the RNA silencing machinery to clinical applications of microRNA antagonists, and from the function of small RNAs in transcription to the delineation of functional networks of small RNAs and RNA-binding proteins in development, immunity, and cancer. Overall, the aim is to create an inspiring interactive forum for basic and clinician scientists working on non-coding RNAs and cancer.
The conference starts at 8:00 (Registration), first talk is at 9:30, and last scheduled talk is at 16:45. Event speakers include:
Frank Slack – Yale University, USA
Joshua Mendell – UT Southwestern Medical Center, USA
Javier Caceres – MRC Human Genetics Unit, UK
Andrea Califano – Columbia University, USA
Eric Miska – Gurdon Institute, UK
Susanna Obad – Santaris Pharma, Denmark
Judy Lieberman – Harvard University, USA
Martin Bushell – University of Leicester, UK
Conference Website:
http://www.ucl.ac.uk/cancer/conferences/micro12_welcome
Conference Location:
Darwin Lecture Theatre, University College London, London, UK
Thanks go to @drgautammehta for pointing this out!
Incoming search terms for this article:
Loading ...
